TIMOTHY J. RICHMOND - 17 Feb 2022 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role: EVP, Chief HR Officer
Signature: Steven L. Scrogham, attorney-in-fact for Timothy J. Richmond
Issuer symbol: ABBV
Transactions as of: 17 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 22 Feb 2022, 16:40:28 UTC
Previous filing: 08 Dec 2021
Next filing: 01 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABBV	Common Stock, $0.01 par value	Award	$0	+22,993		$0.000000	22,993	17 Feb 2022	Direct	F1
transaction	ABBV	Common Stock, $0.01 par value	Award	$0	+4,998	+22%	$0.000000	27,991	17 Feb 2022	Direct	F2
transaction	ABBV	Common Stock, $0.01 par value	Award	$0	+11,978	+43%	$0.000000	39,969	17 Feb 2022	Direct	F3
transaction	ABBV	Common Stock, $0.01 par value	Award	$0	+7,490	+19%	$0.000000	47,459	17 Feb 2022	Direct	F4
transaction	ABBV	Common Stock, $0.01 par value	Award	$0	+13,837	+29%	$0.000000	61,296	17 Feb 2022	Direct	F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABBV	Option (Right to Buy)	Award	$0	+35,026		$0.000000	35,026	17 Feb 2022	Common Stock	35,026	$144.54	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
F2	Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
F3	Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
F4	Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
F5	Represents shares of AbbVie common stock issued under a cliff vesting restricted stock unit award granted to the reporting person on February 17, 2022. The shares will vest in their entirety on the third anniversary of the grant date, subject to the reporting person's continued employment at AbbVie on such date.
F6	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,676 on February 17, 2023, 11,675 on February 17, 2024, and 11,675 on February 17, 2025.